This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Forma Therapeutics Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$395.90m |
| Equity | US$414.49m |
| Total liabilities | US$60.68m |
| Total assets | US$475.17m |
Recent financial health updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Financial Position Analysis
Short Term Liabilities: FMTX's short term assets ($426.4M) exceed its short term liabilities ($33.5M).
Long Term Liabilities: FMTX's short term assets ($426.4M) exceed its long term liabilities ($27.2M).
Debt to Equity History and Analysis
Debt Level: FMTX is debt free.
Reducing Debt: FMTX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FMTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FMTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 18.9% each year.